/

Stylus Medicine

Develops in vivo genetic medicines with recombinases and nanoparticles.

BiotechnologyPharmaceuticals stylusmedicine.com ↗

Company facts

Founded: 2022
Employees: 50
Headquarters: United States
Type: Private
Funding: Series A · $85M · 2025